Related Experiment Video
Updated: Aug 11, 2026

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
Published on: September 19, 2012
The VALUE trial: a commentary
Insights
The VALUE trial found that amlodipine, a calcium channel blocker, was associated with fewer heart attacks and strokes compared to valsartan, an angiotensin receptor blocker. Blood pressure control was the key factor in patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Hypertension Research
Background:
- The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial investigated two antihypertensive strategies: valsartan (angiotensin receptor blocker) versus amlodipine (calcium channel blocker).
- Diuretics were added as needed to achieve blood pressure goals in over 15,000 patients over 4.2 years.
- The study aimed to compare coronary heart disease outcomes between the two treatment groups.
Discussion:
- While the primary composite endpoint for cardiac morbidity and mortality showed no significant difference, amlodipine demonstrated a statistically significant reduction in myocardial infarction and a trend towards reduced stroke events compared to valsartan.
- A non-significant increase in hospitalised heart failure was observed with amlodipine.
- Early achievement of lower blood pressure levels in the amlodipine group likely contributed to its observed benefits.
Key Insights:
- Lowering blood pressure is the primary determinant of outcomes in antihypertensive therapy trials.
- Valsartan treatment was associated with a lower incidence of new-onset diabetes compared to amlodipine.
- Amlodipine showed a potential benefit in reducing cardiovascular events like myocardial infarction and stroke.
Outlook:
- Further research could explore the long-term impact of these antihypertensive strategies on specific cardiovascular endpoints and diabetes incidence.
- The findings underscore the importance of individualized treatment approaches in hypertension management.
- Future trials may focus on optimizing combination therapies to maximize benefits and minimize risks.
Abstract:
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial compared coronary heart disease outcome in two anti-hypertensive treatment strategies based on either an angiotensin receptor blocker, valsartan, or a calcium channel blocker (CCB), amlodipine. In both patient groups a diuretic was added, if necessary, in an attempt to achieve blood pressure (BP) goals. Follow-up of over 15,000 patients was maintained for 4.2 years. There were no differences in the primary composite endpoint of cardiac morbidity and mortality (which included interventional procedures, hospitalised heart failure, non-fatal myocardial infarction and fatal coronary heart disease, however myocardial infarction and stroke events occurred less commonly on amlodipine than on valsartan the former achieving statistical significance [p=0.02 and p=0.08 respectively]). There was a non-significant excess of hospitalised heart failure on amlodipine (p=0.012). However, lower BPs early in the trial probably accounted for most of the observed benefits in favour of the CCB. The angiotensin receptor blocker arm was associated with less new onset diabetes. The results of VALUE add further support to the evidence that blood pressure control is the major determinant in outcome in trials of antihypertensive therapy.
Related Concept Videos
Critical Values
P-value
P-value stands for the probability value. P-value is the probability that, if the null hypothesis is true, the results from another randomly selected sample will be as extreme or more extreme as the results obtained from the given sample.
A large P-value calculated from the data indicates to not reject the null hypothesis. But a higher P-value does not mean that the null hypothesis is true. The smaller the P-value, the more unlikely...
Decision Making: P-value Method
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim is also stated. These statements can act as null and alternative hypotheses: a null hypothesis would be a neutral statement while the alternative hypothesis can have a...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Trial and Error and Algorithm

